Zhenyi Xue

AbbVie (United States) — United States

Medicine · Health Sciences

28h-index2.7kcitations56works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(8), Bioactive Compounds and Antitumor Agents(6), Plant-derived Lignans Synthesis and Bioactivity(6), Liver Disease Diagnosis and Treatment(5), HIV/AIDS drug development and treatment(5)

Publications56 total

Real-World Data of Adherence and Drug Survival of Biologics in Treatment-Naïve and Treatment-experienced Adult Patients with Rheumatoid Arthritis
Advances in Therapy·2023· 13 citedOpen Access
Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study
Scandinavian Journal of Gastroenterology·2022· 5 citedOpen Access
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study
Dermatology and Therapy·2022· 24 citedOpen Access
Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
Clinical Cancer Research·2021· 135 citedOpen Access
Erratum to Thermosensitive injectable hydrogel enhances the antitumor effect of embelin in mouse hepatocellular carcinoma [Journal of Pharmaceutical Sciences 103 (2014) 965–973]
Journal of Pharmaceutical Sciences·2021
Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials
Journal of Viral Hepatitis·2021· 26 citedOpen Access
Arctigenin Exerts Neuroprotective Effect by Ameliorating Cortical Activities in Experimental Autoimmune Encephalomyelitis In Vivo
Frontiers in Immunology·2021· 11 citedOpen Access
Loss of fragile site-associated tumor suppressor promotes antitumor immunity via macrophage polarization
Nature Communications·2021· 34 citedOpen Access
Pin1 Promotes NLRP3 Inflammasome Activation by Phosphorylation of p38 MAPK Pathway in Septic Shock
Frontiers in Immunology·2021· 36 citedOpen Access
HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients
Advances in Therapy·2021· 3 citedOpen Access
Arctigenin Exerts Neuroprotective Effect By Ameliorating Cortical Activities in Experimental Autoimmune Encephalomyelitis in Vivo
2021· 5 citedOpen Access
Arctigenin protects mice from thioglycollate‐induced acute peritonitis
Pharmacology Research & Perspectives·2020· 11 citedOpen Access
Restoration of miR-340 controls pancreatic cancer cell <i>CD47</i> expression to promote macrophage phagocytosis and enhance antitumor immunity
Journal for ImmunoTherapy of Cancer·2020· 57 citedOpen Access
miR-128 Regulates Tumor Cell CD47 Expression and Promotes Anti-tumor Immunity in Pancreatic Cancer
Frontiers in Immunology·2020· 44 citedOpen Access
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection
Liver International·2019· 62 cited
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study
Advances in Therapy·2019· 10 citedOpen Access
miR-21 promotes NLRP3 inflammasome activation to mediate pyroptosis and endotoxic shock
Cell Death and Disease·2019· 153 citedOpen Access
Parthenolide regulates oxidative stress‐induced mitophagy and suppresses apoptosis through p53 signaling pathway in C2C12 myoblasts
Journal of Cellular Biochemistry·2019· 32 cited
Glecaprevir/Pibrentasvir in patients with chronic <scp>HCV</scp> genotype 3 infection: An integrated phase 2/3 analysis
Journal of Viral Hepatitis·2018· 41 citedOpen Access
Analysis of AST to Platelet Ratio Index (APRI) for Determining Eligibility for 8 Weeks of Glecaprevir/Pibrentasvir
The American Journal of Gastroenterology·2018· 1 cited
page 1 of 3Next →

Frequent Co-authors

Rongxin Zhang(36), Yurong Da(30), Zhi Yao(21), Zimu Zhang(14), Qi Zhang(10), Huafeng Wang(10), Hongkun Liu(9), Qing Xi(9), Xixi Cheng(8), Jieyou Zhang(8), Lijuan Zhang(8), Meiyu Peng(8), Shuyu Fu(7), Bingqing Huang(6), Liang Qiao(6), X. Edward Guo(6), Yinghui Ren(6), Guangze Yang(6), Zhenzhen Ge(6), Kai Zhang(6)